Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis

Rognoni, Carla; Marchetti, Monia; Quaglini, Silvana; Liberato, Nicola Lucio

doi:10.1007/s40261-013-0144-3

Cited by 52 publications

(33 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whereas European studies yielded an incremental cost-effectiveness ratio (ICER) ranging from dominance to €20,089 per quality-adjusted life-year (QALY) [16][17][18][19][20], the ICERs of studies conducted in the US or Canada ranged from $3,200 to $55,800 per QALY [21][22][23]. However, to date, no study has evaluated the cost effectiveness of rivaroxaban compared with conventional warfarin for the German healthcare system.…”

mentioning

confidence: 99%

Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation

et al. 2014

View full text Add to dashboard Cite

Our results showed that the substantially higher medication costs of rivaroxaban were offset by mitigating the shortcomings of warfarin, most notably frequent dose regulation and bleeding risk. Future health economic studies on novel oral anticoagulants should evaluate the cost effectiveness for secondary stroke prevention and, as clinical data from direct head-to-head comparisons become available, new anticoagulation therapies should be compared against each other.

show abstract

mentioning

confidence: 99%

Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Since the results of a recent economic evaluation conducted at national level suggest the cost-effectiveness of dabigatran and rivaroxaban compared with warfarin in the prevention treatment of NVAF patients [5], it seemed appropriate to assess the financial impact on the National Health Service (NHS), through a Budget Impact Analysis (BIA) aimed at estimating the sustainability. As a secondary objective, the BIA estimated the economic impact due to the use of idarucizumab in patients treated with dabigatran.…”

Section: Budget Impact Analysis Of Dabigatran Compared With Rivaroxabmentioning

confidence: 99%

Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation

Celeste

Marco

Fresco

et al. 2017

View full text Add to dashboard Cite

BACKGROUND: Dabigatran 150 mg BID (D150) and rivaroxaban 20 mg (R20) are indicated for the prevention of thromboembolic events in patients with Non-Valvular Atrial Fibrillation (NVAF). Outcomes from observational study demonstrated that D150 and R20 reduced the rate of thromboembolic events. OBJECTIVE: This analysis estimated the budget impact of the use of D150 and R20 for the treatment of NAFV patients in Italy. METHODS: A budget-impact model (BIM) was developed to estimate the direct costs up to 12 months from an Italian NHS perspective. The resource utilization (drugs and intracranial hemorrhage or major extracranial bleeding event) was derived from an observational study. Only direct medical costs were considered. Ex-factory prices and National Tariffs were considered to estimate the costs of drugs and medical resource used, respectively. The BIM showed the difference of expenditure and clinical events (intracranial hemorrhage or major extracranial bleeding) generated by the base case calculated for current prescription volumes (D150 30%, R20 100%), and for different prescription volume scenarios (D150 at 70% and 100%). Key variables were tested in the sensitivity analysis. RESULTS: D150 was associated with a medical cost offset driven by fewer intracranial hemorrhage and major extracranial bleeding event, these offset the incremental drug cost and results in an annual saving per patient treated (D150: € 1,052.78; R20: € 1,161.23). The present scenario determines an annual cost of € 262,543,583. The impact of total annual costs for the Italian NHS would be lower if D150 prescription volumes would be higher. The total cost is predicted to decrease by 3.8% if the D150 prescription increase to 70% and it is predicted to decrease by 6.7% if the D150 prescription increase to 100%. CONCLUSION: The use of D150, as an alternative to R20 to prevent events in patients with NVAF, could represent a costsaving option for the Italian NHS.

show abstract

“…Co ciekawe, kontrola INR według wytycznych nie zmieniała ryzyka powikłań krwotocznych oraz incydentów sercowo-naczyniowych (ogólne ryzyko ciężkich krwawień w badanej populacji wynosiło 0,3%, a incydentów sercowo-naczyniowych -0,8% po 30 dniach obserwacji). Warto również przypomnieć o istnieniu danych sugerują-cych, że stosowanie nowych leków przeciwzakrzepowych zamiast warfaryny w populacji pacjentów z niezastawkowym AF jest postępowaniem efektywnym kosztowo, co stanowi ekonomiczny argument za częstszą konwersją schematów leczenia na nowsze [21].…”

Section: Konwersja Z Vka Na Noacunclassified

Doustne antykoagulanty nowej generacji — aspekty praktyczne. Stanowisko Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego

Kasprzak

Dąbrowski²,

Barylski³

et al. 2016

Folia Cardiologica

View full text Add to dashboard Cite

Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis

Abstract: Our analysis suggests that NOAs are a cost-effective treatment for the prevention of stroke in patients with NVAF in the Italian healthcare setting.

Cited by 52 publications

References 40 publications

Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation

Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation

Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation

Doustne antykoagulanty nowej generacji — aspekty praktyczne. Stanowisko Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego

Contact Info

Product

Resources

About